Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 31;13:873576. doi: 10.3389/fimmu.2022.873576

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wang, Du, Li, Li, Wang, Zhao, Meng, Li, Pan, Xia, Wu, Yang, Li, Ma, ZhangBao, Huang, Chang, Tan, Yu, Zhou, Lu, Wang, Dong, Lu, Zhao and Quan

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Nomogram and decision curve analysis in the primary cohort. (A) Nomogram for predicting 1- and 2-year relapse-free probability in the primary cohort. Based on each variable axis of the nomogram, the probability for each patient was determined (upward-pointing line). At the total-points axis, the sum of points corresponds to 1- and 2-year relapse-free probability (downward-pointing line). (B) Decision curve analysis for the Model. The decision curve revealed that if the threshold probability exceeds 0.15, this nomogram was superior for predicting subsequent relapses compared to either treat-all or treat-none scheme. ON, optic neuritis; TM, transverse myelitis; EDSS, Expanded Disability Status Scale; AZA, azathioprine; MMF, mycophenolate mofetil; TAC, tacrolimus; RTX, rituximab; CTX, cyclophosphamide.